Zaleplon (Sonata) is the safer choice for insomnia in stroke patients
For a patient with prior stroke, zaleplon (Sonata) should be preferred over eszopiclone (Lunesta) due to its ultra-short half-life, minimal residual sedation, and lower risk of next-day cognitive and motor impairment—critical safety considerations in stroke survivors who are already at elevated risk for falls, confusion, and further cerebrovascular events.
Rationale Based on Pharmacokinetic Safety Profile
The key differentiator in stroke patients is the risk of residual sedation and cognitive impairment. According to the 2008 AASM guidelines, zaleplon has a very short half-life and consequently is unlikely to result in residual sedation 1. In contrast, eszopiclone has a relatively longer half-life, is more likely to improve sleep maintenance, and is more likely to produce residual sedation 1.
For stroke patients specifically:
- Residual morning sedation increases fall risk, which is particularly dangerous given stroke-related motor deficits and balance impairments
- Cognitive impairment from longer-acting agents can mask or worsen post-stroke cognitive dysfunction
- Next-day psychomotor impairment compounds existing stroke-related motor deficits
Evidence Quality and Guidelines
Both the 2017 AASM guidelines provide weak recommendations for both agents in general insomnia populations 2:
- Eszopiclone: Suggested for both sleep onset AND sleep maintenance insomnia (2-3 mg doses)
- Zaleplon: Suggested for sleep onset insomnia ONLY (10 mg doses)
However, these general recommendations do not account for the specific vulnerabilities of stroke patients.
Stroke-Specific Considerations
A 2024 network meta-analysis specifically examined eszopiclone in post-stroke insomnia 3, finding efficacy when combined with other agents. However, this study did not compare eszopiclone to zaleplon directly and did not specifically address safety concerns unique to stroke patients.
The FDA labeling for both agents warns about:
- Complex sleep behaviors (sleep-driving, amnesia) 4, 5
- CNS depression and next-day impairment 4, 5
- Memory and psychomotor impairment 4, 5
These risks are magnified in stroke patients who may have:
- Pre-existing cognitive deficits
- Motor impairments increasing fall risk
- Polypharmacy with other CNS-active medications
Practical Algorithm for Selection
Choose zaleplon (Sonata) if:
- Primary complaint is sleep onset difficulty (not maintenance)
- Patient has significant motor deficits or fall risk
- Patient has cognitive impairment post-stroke
- Patient needs to maintain alertness for nighttime bathroom trips
Consider eszopiclone (Lunesta) only if:
- Sleep maintenance is the predominant problem AND
- Patient has minimal motor/cognitive deficits AND
- Zaleplon has failed at adequate trial AND
- Benefits clearly outweigh risks after careful assessment
Dosing specifics:
- Zaleplon: 5 mg initially (lower than standard 10 mg given stroke history), taken immediately before bed
- Eszopiclone: If absolutely necessary, 1 mg (lower than standard 2-3 mg), not the 2-3 mg studied in trials
Critical Safety Monitoring
Regardless of choice, stroke patients require:
- Fall risk assessment before and during treatment
- Cognitive function monitoring (watch for worsening confusion)
- Medication review for drug interactions (especially other CNS depressants)
- Trial period of 7-10 days to assess for adverse effects before continuing
- Avoidance of alcohol completely 4, 5
Common Pitfalls to Avoid
- Using standard doses: Stroke patients require lower starting doses than studied populations
- Ignoring sleep maintenance needs: If zaleplon fails due to maintenance issues, consider non-pharmacologic approaches (CBT-I) before escalating to longer-acting agents 1, 6
- Overlooking polypharmacy: Many stroke patients take anticoagulants, antihypertensives, and antidepressants—all potential interactions
- Continuing indefinitely: Both agents should be time-limited with regular reassessment 1
Alternative Consideration
If neither agent is suitable, ramelteon (melatonin receptor agonist) may be considered as it has no CNS depression, no fall risk, and no abuse potential 1, though efficacy is limited to sleep onset only.
The 2016 ACP evidence report notes that observational studies suggest associations between hypnotics and serious harms including falls, confusion, and mortality 7, reinforcing the need for extreme caution in vulnerable populations like stroke survivors.